I have a lipoprotein(a) level of 115 nmol/L; what does this indicate and how should I manage my cardiovascular risk?

Your Lipoprotein(a) Level of 115 nmol/L Indicates Elevated Cardiovascular Risk and Requires Aggressive Management of All Other Risk Factors

Your Lp(a) level of 115 nmol/L exceeds the clinically significant threshold of 100–125 nmol/L established by the European Society of Cardiology, placing you at enhanced risk for atherosclerotic cardiovascular disease, coronary heart disease, and potentially aortic valve stenosis. 1

Understanding Your Risk Level

Your Lp(a) concentration falls into a high-risk category:

• The ESC defines Lp(a) >50 mg/dL (approximately 100–125 nmol/L) as clinically significant for cardiovascular disease risk. 1 Your level of 115 nmol/L sits right at this threshold.

• Traditional risk thresholds are >75 nmol/L (approximately the 75th percentile in white populations), and your level substantially exceeds this cutoff. 2

• Recent data from healthy women followed for 30 years demonstrates that Lp(a) levels above 30 mg/dL (approximately 95 nmol/L) associate with increased risk of major cardiovascular events and coronary heart disease. 3

• Very high Lp(a) is defined as ≥150 nmol/L or >100 mg/dL by the American College of Cardiology, so while your level is elevated, it does not reach the "very high" category. 1

Immediate Management Strategy

1. Aggressive LDL-Cholesterol Lowering

You must be treated with more aggressive LDL-cholesterol targets than age-matched individuals without elevated Lp(a). 1

• Target non-HDL-cholesterol <100 mg/dL (2.5 mmol/L). 4

• The ESC recommends that elevated Lp(a) warrants LDL-C targets that are more stringent than standard recommendations. 1

• If you have or develop acute coronary syndrome, immediate initiation of high-intensity statin with ezetimibe is recommended rather than sequential therapy. 5

2. Comprehensive Cardiovascular Risk Factor Control

Because no specific Lp(a)-lowering therapy is currently approved, intensive management of all modifiable risk factors becomes critical: 1

• Smoking cessation (if applicable) 1
• Optimal blood pressure control 1
• Weight management 1
• Diabetes prevention or optimal glycemic control 1

3. Consider Low-Dose Aspirin for Primary Prevention

• The ESC states that low-dose aspirin may be considered for primary prevention in patients with elevated Lp(a) after individualized assessment of cardiovascular risk versus bleeding risk. 1

4. Avoid Niacin Therapy

• Niacin should NOT be used solely to lower Lp(a) because clinical trials have not demonstrated cardiovascular benefit despite achieving 20–30% reductions in Lp(a) levels. 1, 6

Monitoring and Follow-Up

• Lp(a) levels remain relatively constant throughout life, so repeat testing is generally not necessary unless you are enrolled in a clinical trial or considering experimental therapies. 6

• The ESC recommends measuring Lp(a) at least once in adulthood, which you have now completed. 5

Family Screening Considerations

• Cascade testing has potential value given your elevated Lp(a), as levels are highly heritable and first-degree relatives may also have elevated levels. 7

• Consider recommending Lp(a) testing for first-degree relatives, particularly those with personal or family history of premature cardiovascular disease. 4

Future Therapeutic Options

• Antisense oligonucleotides (ASO) targeting Lp(a) can reduce levels by up to 90% and are under investigation in the ongoing Lp(a)HORIZON cardiovascular outcomes trial. 6

• PCSK9 inhibitors reduce Lp(a) by up to 30% and may be considered if you require additional LDL-cholesterol lowering. 6

• Lipoprotein apheresis is reserved for patients with very high Lp(a) (typically >200 nmol/L) who experience progressive cardiovascular disease despite optimal management of all other risk factors. 1, 4 Your current level does not meet this threshold.

Clinical Pitfalls to Avoid

• Standard LDL-cholesterol assays include Lp(a)-cholesterol, which can falsely elevate your measured LDL-C and make target achievement appear more difficult. 1

• Statins may paradoxically increase Lp(a) levels, though their cardiovascular benefits through LDL-lowering far outweigh this effect. 1

• Do not delay aggressive risk factor modification while waiting for specific Lp(a)-lowering therapies to become available. 7